The most promising trial data so far is from the BioNtech Lipo-MERIT trial in which patients with advanced melanoma were given 8 RNA-LPX vaccinations with a vaccine encoding four classic melanoma tumour antigens (NY-ESO-1, Tyrosinase, MAGE-A3, and TPTE) with or without anti-PD1 [12]. Here, TYR is linked to melanoma.